Navigating Turbulence | Agios faces challenges in the sickle cell disease market while pursuing opportunities in thalassemia and myelodysplastic syndromes, shaping its strategic direction. |
Financial Fortitude | With a robust $1.7 billion cash position, Agios stands ready to fund pipeline development and explore strategic opportunities in the biopharma landscape. |
Pipeline Potential | Explore Agios' diverse portfolio, including Pyrukynd's label expansion and emerging therapies, poised to drive future growth in genetic diseases and oncology. |
Market Dynamics | Analyst targets range from $55 to $56, reflecting cautious optimism amidst regulatory uncertainties and potential market share gains in sickle cell disease. |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Metrics to compare | AGIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGIOPeersSector | |
---|---|---|---|---|
P/E Ratio | 3.8x | −1.4x | −0.6x | |
PEG Ratio | 0.01 | −0.01 | 0.00 | |
Price/Book | 1.6x | 2.5x | 2.6x | |
Price / LTM Sales | 77.8x | 10.9x | 3.2x | |
Upside (Analyst Target) | 23.7% | 227.9% | 48.6% | |
Fair Value Upside | Unlock | 13.3% | 7.0% | Unlock |